Clinical Trial Update: Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists [Phase 4]

View source ↗

Summary

Phase 4 trial results evaluate the efficacy of omalizumab in adults aged 18-60 with moderate-to-severe persistent allergic asthma who remain uncontrolled on inh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Allergic Asthma | Phase 4 | Status: COMPLETED | Results posted: 2013-01-18